Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC
Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC
First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
ASCO 2026: Highlights and analysis
Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer
Omission of axillary lymph node dissection reduces arm morbidity without compromising survival in select breast cancer cases
Combination therapeutic strategies for aRCC patients with bone metastases
Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer
Distinct lung microbiome patterns identified in Portuguese patients with lung cancer
EAU 2026: Updates in NMIBC
Real-world cardiovascular risks with novel hormonal therapies in advanced prostate cancer